D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how D3L-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D3L-001 is under development for the treatment of HER2 positive breast cancer, gastric cancer, gastroesophageal junction carcinomas and solid tumors. It is a bi-specific monoclonal antibody and acts by targeting HER2 and CD47. It is administered through intravenous route.
D3 Bio overview
D3 Bio provides healthcare-related services. It is headquartered in Zhejiang, China.
For a complete picture of D3L-001’s drug-specific PTSR and LoA scores, buy the report here.